Privia Health $525.8 million IPO
We advised Privia Health on its IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Avid Bioservices $143.8 million exchangeable senior notes offering
We advised the initial purchasers on the Rule 144A offering
Owens & Minor $500 million notes offering
We advised the initial purchasers on the high-yield notes offering
PerkinElmer $800 million notes offering
We advised the joint bookrunners on the investment-grade debt offering
Cornell Capital acquires trustaff and CardioSolution in combination with Stella
We are advising Cornell Capital on the acquisition
Cryoport $287.5 million follow-on offering
We advised the underwriters on the SEC-registered offering
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…
Seer $336 million IPO and concurrent private placement
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 10,592,106 shares of Class A common stock of Seer, Inc. at $19.00 per…
Revance Therapeutics $125 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its common stock for up to an aggregate amount of $125 million.
Based…
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…